Personalized neoantigen tumor vaccine is named as an intervention in 5 current clinical trials in our China register. 4 are recruiting patients now. The most common phase is Phase EARLY_PHASE1. The sponsor with the most trials is Ruijin Hospital (4). The most-studied condition is B-cell Non-Hodgkin's Lymphoma (B-NHL).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors
NCT05916248 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
|
Phase EARLY_PHASE1 | Recruiting | Ruijin Hospital | China |
|
Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer
NCT05916261 · ClinicalTrials.gov ↗ · Advanced Pancreatic Cancer
|
Phase EARLY_PHASE1 | Recruiting | Ruijin Hospital | China |
|
Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer
NCT06496373 · ClinicalTrials.gov ↗ · Pancreatic Cancer Resectable, Chemotherapy-intolerant
|
Phase EARLY_PHASE1 | Recruiting | Ruijin Hospital | China |
|
XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia
NCT06980155 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia
|
Phase EARLY_PHASE1 | Recruiting | Shanghai Jiao Tong University School of Medicine | China |
|
Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL
NCT07334574 · ClinicalTrials.gov ↗ · B-cell Non-Hodgkin's Lymphoma (B-NHL)
|
Phase 1 | Not yet open | Ruijin Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Ruijin Hospital | 4 |
| Shanghai Jiao Tong University School of Medicine | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 5 | 4 |
A trial with sites in more than one country appears in each of those registers.
5 current trials in our China register name Personalized neoantigen tumor vaccine as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 5 trials are recruiting: 4 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Ruijin Hospital (4) and Shanghai Jiao Tong University School of Medicine (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Personalized neoantigen tumor vaccine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Personalized neoantigen tumor vaccine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Personalized neoantigen tumor vaccine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.